CLSI’s Fellows All-Star Team (FAST) accelerator has achieved some outstanding benchmarks through its 29 company graduates: in just six cycles, FAST companies have raised more than $115M and have created over 125 jobs. A quarter of these graduates have entered the commercial space, eleven have received Series A investments, eight are shipping product, five have instrumentation in the field, two med devices have gone into clinical trials, and 1 company has successfully exited.
These are the aggregate successes of the remarkable life science startups who have comprised the FAST program to date. The program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Some additional recent graduate successes include:
GigaGen, a biopharmaceutical company developing novel antibody and T cell therapies derived from immune repertoires, has announced the approval of their patent for polyclonal antibody production. Link to press release
FAST graduate Shasqi has a recent publication in ACS Central Science, In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug to Treat Soft Tissue Sarcoma. Press Release 1; Press Release 2
Last but not least, congratulations to Paragon Genomics and EpiBiome for their recent acceptance into the StartX Med 2016 Fall Accelerator Program!